Rotational thrombelastometry (ROTEM) improves hemostasis assessment compared to conventional coagulation test in ACLF and Non-ACLF patients.

Jessica SeeßleJan LöhrMarietta KirchnerJosefin MichaelisUta Merle

Published in: BMC gastroenterology (2020)

For assessing hemostasis in Non-ACLF and ACLF patients the underlying dataset shows advantages of ROTEM over CCT. A10 and MCF represent suitable prognostic parameters in predicting bleeding events in ACLF group.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
atrial fibrillation
patient reported
breast cancer cells